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Abstract 
Context 
Cancer and symptom experiences of adolescents and young adults (AYAs) with cancer can be highly 
variable, creating challenges for clinicians and researchers who seek to optimize AYAs' health 
outcomes. Understanding the heuristics AYAs use to designate priority symptoms can provide insight 
into the meaning they assign to their symptoms and self-management behaviors. 
Objectives 
This study described the frequency and characteristics of priority symptoms. It qualitatively explored 
reasons for a symptom's designation as a priority symptom, perceived causes of priority symptoms, 
and strategies AYAs use to manage priority symptoms. 
Methods 
Participants in this single-group, longitudinal study reported symptoms using a heuristics-based 
symptom reporting tool, the Computerized Symptom Capture Tool, at two scheduled visits for 
chemotherapy. AYAs designated priority symptoms and responded to three short answer questions: 
What makes this a priority symptom?, What do you think causes it?, and What do you do to make it 
better? 
Results 
Eighty-six AYAs, 15–29 years of age (median 19 years), identified 189 priority symptoms. Priority 
symptoms were of greater severity (t = 3.43; P < 0.01) and distress (t = 4.02; P < 0.01) compared with 
nonpriority symptoms. Lack of energy, nausea, difficulty sleeping, and pain comprised 39% of priority 
symptoms. Reasons for priority designation included the impact of the symptom and the attributes of 
the symptom. Categories of self-management strategies included “Physical Care Strategies,” “Things I 
take (or not),” and “Psychosocial Care Strategies.” 
Conclusion 
Supporting AYAs to identify their priority symptoms may facilitate a more personalized approach to 
care. Seeking the patient's perspective regarding priority symptoms could enhance patient-clinician 
collaboration in symptom management. 
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Introduction 
The National Cancer Institute (NCI) defines adolescents and young adults (AYAs) as patients between 
the ages of 15 and 39 years based on types of cancers AYAs are more likely to acquire and evidence 
that indicates some of these cancers may have unique genetic and biological characteristics.1 During 
the transition from adolescent, to emerging adult, to young adult, AYAs' attainment of physiological 
maturity, independence, and assumption of traditional adult roles in society is multidimensional and 
very individual.2 As a result, AYAs' cancer and symptom experiences are highly variable and dynamic, 
creating challenges for clinicians and researchers who seek to optimize AYAs' health outcomes. 
These developmental factors have important implications for the health-related behaviors of AYAs 
with cancer, including how they interpret their symptoms and make self-management decisions. The 
heuristics, or mental rules, AYAs use to interpret their illness and symptoms are based on cognitive 
processing, prior experiences, cultural beliefs, and social comparisons.3 Understanding AYAs' symptom 
heuristics can provide insight into their self-management behaviors and the meaning they assign to 
their symptoms. 
To partner with AYAs in managing their symptoms, providers need a consistent approach to elicit the 
symptoms AYAs are experiencing, including those which are of priority to them. Standard approaches 
to symptom assessment with AYAs with cancer do not exist. Measures and indices of symptoms and 
symptom burden have been developed for adults with varying types of cancer.4, 5, 6, 7, 8, 9 The 
development of many of these measures included patient perspectives around the most bothersome 
and most important symptoms. Although the measures were developed around the concept of priority 
symptoms, many of these measures are intended to provide an overall assessment, or score, of the 
patient's overall symptom burden, health-related quality of life, and response to treatment. Although 
patient perceptions and priorities in symptom assessment and management are encouraged,10, 11 
reports soliciting patient priorities at the individual level within a clinical encounter are lacking. 
A recent study asked women with recurrent ovarian cancer to identify the top three symptoms for 
which they would like to get better control, that is, what are their priority symptoms.12 Provider 
documentation and management of priority symptoms were then examined. Although the top four 
priority symptoms (fatigue, peripheral neuropathy, sleep disturbances, and pain) reported by women 
were also most frequently documented by providers, 53% of all priority symptoms were not 
documented by the provider. This lack of documentation suggests that providers may not specifically 
ask patients to assign priority to their symptoms. 
Having AYAs identify their own priority symptoms, the symptoms that are most important to them, is 
consistent with the concept of personalized health care. Personalized medicine is defined by the 
National Institutes of Health as “an emerging approach for disease treatment and prevention that 
takes into account individual variability in genes, environment, and lifestyle for each person.”13 
Personalized health care is the broader term and is defined as “the tailoring of medical management 
and patient care to the individual characteristics of each patient”14 and includes, for example, 
identification of patients' priorities to be used as guiding principles for collaborative care.15 In addition 
to medical management, the concept of personalized health care includes the self-management of 
symptoms. Thus, symptom self-management calls for a patient-centered approach, demonstrating the 
need for patients to be able to identify and voice their priority symptoms. The desire for this 
individualized approach has been expressed by individuals with cancer in other symptom management 
studies.16 The Computerized Symptom Capture Tool (C-SCAT) developed by the investigators17 allows 
AYAs to efficiently and precisely identify not only all symptoms they are experiencing, but more 
importantly, symptoms that are priorities to them. 
Purpose 
This study explored priority symptoms identified by AYAs receiving chemotherapy and the heuristics 
they use in relation to those symptoms. Specifically, this study described and compared the frequency 
and characteristics of priority and nonpriority symptoms. The study also qualitatively explored reasons 
why a given symptom was identified as a priority symptom, perceived causes of priority symptoms, 
and strategies AYAs use to manage priority symptoms. 
Methods 
Design 
This study used a single-group, longitudinal, mixed-methods design in which participants reported 
symptoms at two scheduled visits for receipt of chemotherapy. Participants used the C-SCAT, a 
heuristics-based symptom reporting tool, to relate their symptom experiences during the previous 
24 hours. 
Sample and Setting 
Eligible participants were AYAs 15–29 years of age receiving myelosuppressive chemotherapy as 
treatment for cancer. An age range narrower than that designated by the NCI was selected to recruit a 
study sample more likely to have similar life experiences compared with AYAs 30 years of age and 
older.18, 19 Participants were required to have completed at least one cycle of chemotherapy and 
anticipated to receive at least two additional cycles to be able to complete all study visits. Additional 
inclusion criteria were the ability to read, speak, and understand English and be physically and 
cognitively capable of completing study procedures. Participants were recruited from five academic 
medical centers in the Southeast, Midwest, Intermountain West, and Southwest United States treating 
AYAs with cancer. 
Study Measure 
The study measure was the C-SCAT, an investigator-developed, heuristic-based symptom reporting tool 
that is administered via a tablet computer.17 Users create a graphical image of their symptom 
experiences by selecting symptoms from a menu of 32 symptoms included in the Memorial Symptom 
Assessment Scale (MSAS)20 that they have experienced during the previous 24 hours. They identify the 
perceived cause of each symptom and rate each symptom's severity and distress using the scales from 
the MSAS. Severity is measured on a 1–4 scale with 1 = slight to 4 = very severe. Distress is measured 
on a 0–4 scale with 0 = none to 4 = very much, recognizing that the presence of a symptom may or may 
not be perceived as distressing. Users then identify temporal and causal relationships between 
symptoms and have the option to designate clusters, or groups, of symptoms that they perceive to 
occur together. Finally, users identify priority symptoms within each cluster, “Tap the most important 
symptom in each group. If you did not draw any groups, tap the symptom that is most important to 
you.” As users designate priority symptoms, they are asked: 1) What makes this a priority symptom? 
and 2) What do you do to make it better? Output includes a final image (Fig. 1) and an .xml file 
containing text-based data. 
 
Fig. 1. C-SCAT image from a 16-year-old boy with acute lymphoblastic leukemia. The participant 
identified a total of nine symptoms. Green lines between symptoms indicate a perceived relationship 
between the symptoms. Blue arrows indicate perceived causal relationships. Five symptoms were 
grouped into two clusters, designated and named by the AYA, “Eating and Energy” and “Fatigue.” 
Priority symptoms, those perceived by the AYA as most important within each cluster, are designated 
with red ribbons and are “weight loss” and “lack of energy.” The priority cluster, or group of 
symptoms, perceived as being the most important group, “Fatigue,” is designated with a blue ribbon. 
AYA = adolescent and young adult; C-SCAT = Computerized Symptom Capture Tool. (For interpretation 
of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
Study Procedures 
Institutional review board approval was granted from each study site. Study team members routinely 
screened clinic and inpatient admission schedules for potentially eligible participants. Among AYAs 
who met preliminary screening criteria, reasons for ineligibility were most frequently related to the 
patient's treatment plan, specifically uncertainty about the exact number of additional chemotherapy 
cycles. Written assent and written parental permission were obtained for patients aged 15 to 17 years. 
Patients aged 18 years and older provided written informed consent. At the enrollment visit, AYAs 
provided baseline demographic information about themselves using Research Electronic Data Capture 
(REDCap).21 Clinical data, including diagnosis, months since initial diagnosis, and disease status, were 
identified through medical record review. 
A study team member met with the AYA before each of the next two scheduled visits for 
chemotherapy administration (Visits 1 and 2) to review study procedures and be available as a 
resource while AYAs completed the C-SCAT. AYAs received a copy of their C-SCAT-generated image to 
review with their provider. They also received a gift card after each visit. 
Data Management and Analysis 
Quantitative Data 
Demographic data from REDCap and quantitative C-SCAT-generated data were imported into SPSS files 
for analyses. Descriptive statistics and measures of central tendency characterized the study sample 
and the frequencies of symptoms, priority symptoms, and their associated characteristics. 
Independent-sample t-tests compared the severity and associated distress of priority versus 
nonpriority symptoms. Chi-square analyses compared differences in frequencies of categories of AYAs' 
responses. 
Qualitative Data 
Qualitative data from C-SCAT files were organized into Excel files to support coding procedures. 
Qualitative content analysis procedures22, 23 were used to analyze AYAs reported: 1) reasons for 
designating a given symptom as a priority symptom, 2) perceived causes of the priority symptom, and 
3) strategies used to alleviate the symptom. Authors reviewed responses across questions to gain a 
sense of the data as a whole and perspective of how responses to one question may have also been 
reflected in responses to the other two questions. Each question was then analyzed independently 
with individual responses treated as the unit of analysis.22, 23 Four investigators (L. A. L., C. F. M., A. R. 
N., K. S.) reviewed data independently and assigned preliminary codes. They then met together to 
review codes. Discrepancies were infrequent and were resolved through discussion to reach consensus 
for all coded responses. Codes were further organized into categories and subcategories. 
Results 
Participants 
Eighty-eight AYAs enrolled in the study, and 86 completed at least one C-SCAT visit. Recruitment rates 
averaged 76% across sites. The most frequent reason for declining was lack of interest. Reasons for 
withdrawal included completion of therapy before C-SCAT visits could be completed and a parent's 
decision to withdraw his son after further reviewing the parental permission and participant assent 
documents. Participants were a median of 19 years of age (range 15–29), and a median of five months 
(range 1–48) since initial diagnosis. Demographic characteristics of AYAs who completed at least one C-
SCAT visit are included in Table 1. 
Table 1. Participant Characteristics 
Characteristic N % Mean (SD) Median Range 
Gender 
     
 Male 45 52.3 
   
 Female 41 47.7 
   
Age (yrs) 
  
21 (5.0) 19 15–29 
Age group 
     
 Adolescent (15–18 yrs) 40 46.5 
   
 Young Adult (19–29 yrs) 46 53.5 
   
Race 
     
 White 61 70.9 
   
 Other/more than one race 12 14 
   
 African-American 10 11.6 
   
 Native American/Alaska Native 2 2.3 
   
 Asian 1 1.2 
   
Ethnicity 
     
 Non-Hispanic 67 77.9 
   
 Hispanic 19 22.1 
   
Diagnosis 
     
 Acute lymphoblastic leukemia 27 31.3 
   
 Hodgkin lymphoma 13 15.1 
   
 Sarcoma 10 11.6 
   
 Brain tumor 8 9.3 
   
 Breast cancer 7 8.1 
   
 Non-Hodgkin lymphoma 7 8.1 
   
 Acute promyelocytic leukemia 4 4.7 
   
 Other 4 4.7 
   
 Acute myelogenous leukemia 3 3.5 
   
 Chronic myelogenous leukemia 3 3.5 
   
Disease status 
     
 Initial diagnosis 82 95.3 
   
 Relapsed/refractory disease 3 3.5 
   
 Secondary 1 1.2 
   
Months since initial diagnosis 
  
11.7 (13.1) 5 1–48 
 
Symptoms 
At Visit 1, AYAs reported a total of 468 symptoms (mean = 5.44; SD = 4; range = 0–15). Eighty-nine of 
these symptoms were designated as priority symptoms (median = 1; range = 0–3). At Visit 2, AYAs 
reported a total of 377 symptoms (mean 4.44; SD = 3.8; range 0–18). Eighty of these symptoms were 
designated as priority symptoms (median = 1; range = 0–3). Table 2 reports the most frequently 
reported symptoms. 
Table 2. Most Frequently Reported Symptoms Across Visits 
Symptom n 
Lack of energy 71 
Feeling drowsy 53 
Difficulty sleeping 52 
Pain 51 
Nausea 48 
Hair loss 46 
Feeling irritable 38 
Changes in how food tastes 37 
Lack of appetite 33 
Tingling in hands/feet 33 
 
Twenty-nine of the 32 symptoms included in the C-SCAT were designated as a priority symptom at 
least once. Priority symptoms were reported as more severe (t = 3.43; P < 0.01) and distressing 
(t = 4.02; P < 0.01) compared with nonpriority symptoms. Priority symptoms were of moderate or 
greater severity on 83% of occasions and of somewhat or greater distress on 68% of occasions. Fig. 2 
summarizes the 11 most frequent priority symptoms across visits along with the occasions each 
priority symptom was rated as of moderate or greater severity and distress. Three symptoms were 
never named as priority symptoms: dry mouth, problems with urination, and swelling in arms and legs. 
 
Fig. 2. Summary of most frequent priority symptoms and frequency with which these symptoms were 
of moderate or greater severity and somewhat or greater distress. 
Lack of energy, nausea, difficulty sleeping, and pain comprised 39% of all reported priority symptoms. 
For these four symptoms, severity and distress did not differ based on priority designation (Table 3). 
These symptoms were also of moderate or greater severity on more than 80% of reported occasions 
regardless of priority designation. 
Table 3. Comparison of Symptom Severity and Distress for Four Most Frequent Priority Symptoms 
Priority Symptom Mean Severity (SD)a  Mean Distress (SD)b   
Priority Nonpriority Priority Nonpriority 
Lack of energy 2.3 (0.7) 2.1 (0.7) 1.8 (0.8) 1.9 (1.2) 
Nausea 2.2 (0.71) 2.2 (0.8) 2.4 (1.3) 2.0 (1.1) 
Difficulty sleeping 2.2 (0.8) 2.0 (0.7) 2.2 (0.9) 1.9 (1.2) 
Pain 2.6 (1.0) 2.3 (0.7) 2.7 (0.8) 2.4 (1.2) 
aDifferences in severity not statistically significant based on priority/nonpriority designation. 
bDifferences in distress not statistically significant based on priority/nonpriority designation. 
 
Reasons for Designating a Symptom as Priority 
Participants provided 153 responses to the question, “What makes this a priority symptom?” These 
responses were organized into 158 codes that were organized into three categories (Impact of 
Symptoms, Attributes of Symptoms, Don't Know) and seven subcategories (Table 4). Definitions of 
categories and subcategories arose from the AYAs' responses. Post hoc comparisons indicated that 
AYAs' reasons for designating a symptom as priority did not differ based on the visit (Visit 1 vs. Visit 2) 
(Χ2 = 2.66; P = 0.85). Reasons for designating a symptom as priority also did not differ based on 
whether the symptom was one of the four most frequently reported priority symptoms versus the 
other priority symptoms (Χ2 = 8.94; P = 0.18). 
Table 4. Categories and Subcategories of Reasons for a Symptom's Designation as Priority 
Categories and 
Subcategories 
Frequency 
(%) 
Example 
Impact of the 
symptom 
101 (63.9) 
 
 Physical impact 36 “Nausea makes me feel sick and it decreases my appetite” 
(Nausea, 16 y/o F with Hodgkin lymphoma [HL]) 
“It makes the rest of my body weaker” (Lack of energy, 
19 y/o M with rhabdomyosarcoma [RMS]) 
“It makes me feel bloated and nauseous” (Constipation, 
19 y/o M with RMS) 
 Well-being 34 “I need sleep and energy to get better” (Difficulty sleeping, 
15 y/o M with acute lymphoblastic leukemia [ALL]) 
“Interferes with interpersonal interactions, not as even-
tempered as usual” (Feeling irritable, 29 y/o F with breast 
cancer) 
 Functional status 16 “Because I can't do basic daily activities such as cooking” 
(Lack of energy, 28 y/o F with breast cancer) 
“I need to think clearly, focus, and be concentrated in day-to-
day life” (Difficulty concentrating, 16 y/o M with ALL) 
 Emotional impact 15 “Anxious about appointments” (Difficulty sleeping, 29 y/o F 
with metastatic adenocarcinoma) 
“This was my biggest fear” (Hair loss, 23 y/o M with ALL) 
Attributes of the 
symptom 
56 (35.4) 
 
 Severity/distress 34 “It makes me feel the worst” (Nausea and constipation, 
17 y/o F with HL) 
“Pain is the most noticeable” (Pain, 23 y/o F with non-
Hodgkin lymphoma [NHL]) 
“It bothers me the most” (Feeling bloated, 17 y/o F with HL) 
 Causes the others 11 “Causes the rest of the symptoms” (Difficulty sleeping, 29 y/o 
F with ALL) 
“I believe it leads to the rest” (Worrying, 28 y/o F with breast 
cancer) 
“It causes the other symptoms” (Changes in how food tastes, 
16 y/o F with sarcoma) 
 Temporality 11 “Most prevalent” (Feeling bloated and lack of energy, 24 y/o 
male with HL) 
“Constant symptom” (Vomiting, 25 y/o F with acute 
promyelocytic leukemia) 
“I have felt this during the whole cancer process” (Feeling 
sad, 26 y/o F with NHL) 
Don't know 1 (1.0) 
 
 
The Impact of Symptoms category (n = 101) included four subcategories. Physical impact (n = 36) was 
most frequently named and reflected the immediate physical consequences of the symptom such as, 
“If nauseous then that causes me to throw up,” (15-year-old boy with acute lymphoblastic leukemia 
[ALL]). Well-being (n = 34) encompassed AYAs' awareness of what they perceived to be healthy 
behaviors and how the given symptom affected these behaviors, “I need good sleep,” (29-year-old 
woman with adenocarcinoma). 
Priority symptoms adversely impacted AYAs' functional status (n = 16), that is, their ability to perform 
expected day-to-day roles, such as “Makes doing daily activities difficult,” (26-year-old man with ALL). 
The emotional impact of the symptom (n = 15), such as “I miss my hair” (23-year-old man with ALL), 
also resulted in its designation as a priority symptom. 
The Attributes of Symptoms category (n = 56) contained three subcategories. The severity and/or 
distress associated with a given symptom (n = 34), as in “It bothers me the most” (17-year-old girl with 
Hodgkin lymphoma), was the most frequently reported attribute. Other named attributes of a 
symptom that resulted in its designation as a priority symptom included its perception as a symptom 
that caused other symptoms (n = 11), “I believe it leads to [the] rest,” (28-year-old woman with breast 
cancer) or its temporality, that is, its persistence or frequency over time (n = 11), “It happens every 
day” (26-year-old woman with a brain tumor). 
Perceived Causes of Priority Symptoms 
AYAs provided 123 responses to the question, “What do you think caused it [the priority symptom]? 
These responses were organized into 135 codes that were further organized into four categories: 
chemotherapy/treatment (n = 91), other health conditions (n = 22), psychosocial factors (n = 11), and 
don't know (Table 5). Post hoc comparison of frequencies of perceived causes did not differ based on 
the visit (Χ2 = 4.64; P = 0.20) or whether a symptom was one of the four most frequently reported 
priority symptoms versus the other priority symptoms (Χ2 = 1.40; P = 0.71). 
Table 5. Categories and Subcategories of Perceived Causes of Priority Symptoms 
Categories/Subcategories Frequency 
(%) 
Example 
Chemotherapy/Treatment 91 (67.4) 
 
 Medications 71 “Chemo” or “chemotherapy” (multiple patients 
with various diagnoses) 
“My medicine” (Lack of energy, 17 y/o M with brain 
cancer) 
“Meranol” (Difficulty sleeping, 15 y/o M with acute 
lymphoblastic leukemia [ALL]) 
 Cancer and treatment-related 
symptoms 
11 “Feet pain possibly caused by vincristine” (Pain, 
16 y/o F with non-Hodgkin lymphoma [NHL]) 
“Hair loss” (Don't look like myself, 16 y/o F with 
NHL) 
 Experience of going through 
treatment 
9 “Tough scheduling appointments every day …” 
(Difficulty sleeping, 19 y/o M with 
rhabdomyosarcoma [RMS]) 
“Surgery …” (Tingling in hands, 20 y/o M with RMS) 
Other physical condition 22 (16.3) “Dizziness” (Nausea, 17 y/o M with NHL) 
“Back problems” (Pain, 28 y/o F with ALL) 
Psychosocial cause 11 (8.1) “Anxiety” (Nausea, 23 y/o F with NHL) 
“Mixed emotions from chemotherapy” (Worrying, 
16 y/o F with NHL) 
Don't know 11 (8.1) 
 
 
The medications that AYAs were receiving as part of their cancer treatment, such as “chemo,” 
“vincristine,” and “going off prednisone,” predominated as perceived causes. AYAs also identified other 
cancer-related symptoms as causing priority symptoms such as “lack of sleep” as causing fatigue and 
“lack of appetite” causing weight loss. The larger cancer and treatment experience was also reflected 
in perceived causes such as “The whole process I have to go through” and “Tough scheduling for 
appointments everyday.” 
Although less frequently reported, AYAs' responses included other health conditions that were not 
specific to their cancer. These included perceived causes such as “allergies,” “Crohn's disease,” and 
“back problems.” Psychosocial factors perceived as causes of priority symptoms included “stress,” 
“anxiety,” “scary thoughts,” and “circumstances.” Eleven responses included “don't know” as the 
perceived cause. 
Strategies for Self-Managing Priority Symptoms 
AYAs provided 140 responses to the question “What do you do to make it [the priority symptom] 
better? These responses were organized into 174 codes that were further organized into five 
categories: “Physical Care Strategies,” “Something I Take (or not),” “Psychosocial care Strategies,” 
“Nothing,” and “Don't Know” (Table 6). Post hoc comparison of frequencies of self-management 
strategies did not differ based on the visit (Χ2 = 2.39; P = 0.79). Self-management strategy frequencies 
differed based on whether a symptom was one of the four most frequently reported priority symptoms 
(Χ2 = 19.44; P < 0.01). AYAs more frequently reported taking medications (or not) to manage nausea, 
pain, and difficulty sleeping. Psychosocial strategies were more frequently reported to manage the less 
prevalent priority symptoms, particularly those with a psychological component, such as feeling 
irritable, worrying, and feeling nervous. 
Table 6. Categories of Strategies for Self-Managing Priority Symptoms 
Categories Frequency 
(%) 
Example 
Physical care 
strategies 
101 (59.4) “Try to relax or sit down” (Pain, 16 y/o F with non-Hodgkin 
lymphoma [NHL]) 
“Ice, rest, massage, acupuncture” (Pain, 29 y/o F with acute 
lymphoblastic leukemia [ALL]) 
“Just eat the foods I can” (Changes in how food tastes, 16 y/o F 
with sarcoma) 
“Shorter activity or more recovery, take it easier when 
exercising” (Shortness of breath, 29 y/o F with breast cancer) 
Things I take (or 
not) 
42 (24.7) “Take medicine” (Nausea, 15 y/o M with ALL) 
“Sometimes not taking my pills” (Difficulty sleeping, 19 y/o M 
with ALL) 
“Take Miralax or another laxative” (Constipation, 17 y/o F with 
NHL) 
Psychosocial care 
strategies 
19 (11.2) “Distract myself with music” (Worrying, 28 y/o F with breast 
cancer) 
“Try to relax and think” (Difficulty concentrating, 16 y/o M with 
ALL) 
“Reframe angry thoughts” (Feeling irritable, 29 y/o female with 
breast cancer) 
Nothing 10 (4.1) “Nothing” 
“Can't do much right now” (Don't look like myself, 17 y/o F with 
NHL) 
Don't know 2 (1.0) “No idea” (Difficulty concentrating, 16 y/o M with 
rhabdomyosarcoma) 
 
Physical care strategies were most frequently reported (n = 101) and reflected a variety of efforts 
including managing rest and activity, adjusting eating habits, and the use of integrative therapies. 
“Something I take (or not)” (n = 42) included both prescribed and over-the-counter medications, 
particularly for managing pain and nausea. Responses also reflected AYAs' choices in relation to their 
medications. These choices included intentional nonadherence to prescribed treatment-related 
medications, for example, one AYA reported, “Sometimes not taking my medicine,” to alleviate 
difficulty sleeping. Another AYA related how she made choices with a prescribed pain medication in an 
effort to alleviate constipation, “Reduce Oxy intake and take Miralax.” 
Psychosocial care strategies (n = 19) included both intrapersonal efforts, such as “Reframe angry 
thoughts,” and interpersonal strategies, “Being with family.” Ten responses indicated a lack of an 
effective self-management strategy either as “nothing” or ineffective past efforts such as, “I've try 
some thing (sic) but nothing seems to work.” 
Discussion 
This study explored symptoms reported by AYAs with cancer before receiving a cycle of chemotherapy 
and specifically sought insight into the symptoms the AYAs identified as “priority symptoms.” 
Consistent with previous reports, AYAs reported multiple symptoms during treatment, with some 
participants reporting over 15 concurrent symptoms.24, 25, 26 This high number is especially concerning 
because symptom self-reports were collected before the administration of chemotherapy, a time when 
the presence of symptoms is expected to be low. 
Fatigue, difficulty sleeping, nausea, and pain were the most frequent priority symptoms and among the 
most frequently reported symptoms overall. Given that these symptoms contribute to a higher 
symptom burden27, 28, 29 and that they were of moderate or greater severity more than 80% of 
reported occasions, a report of these symptoms warrants clinician attention regardless of priority 
designation. 
Not expected was the finding that all but three symptoms included in the C-SCAT were identified by 
AYAs as priority symptoms at least once. These symptoms included other physical symptoms, such as 
lack of appetite, hair loss, and tingling in hands and feet, as well as psychological symptoms and 
responses, such as worry and feeling irritable. Furthermore, this research indicates that the priority 
symptoms AYAs identified were not always apparent.24 For example, one cluster of symptoms that an 
AYA identified included dizziness, dry mouth, and feeling drowsy. The priority symptom was feeling 
drowsy, which is not obvious and would require further assessment. Although symptoms such as hair 
loss may not have a present remedy, acknowledging their presence and significance to the AYA may be 
a “solution” in and of itself. In addition, the clinician could recommend resources to help alleviate 
distress associated with the symptom. 
Study findings also emphasize the relevance of inquiring about the reason for a symptom's designation 
of priority, a feature lacking in most measures that include ratings of severity and distress.30, 31 Most of 
the reasons for symptoms' priority designations were not their severity or distress but rather their 
effects on the body. These effects included function, as well as general physical and emotional well-
being. 
Consistent with results from the initial study using the C-SCAT,24 priority symptoms were most 
frequently ascribed to cancer and cancer treatment. These findings also align with reports examining 
symptom experiences of adults with cancer, who largely associate their symptoms with cancer-related 
morbidity and treatment.32 AYAs' frequent attribution of their priority symptoms to cancer and cancer 
treatment underscores the need to engage and encourage them to discuss their symptom experiences. 
If AYAs believe their symptoms are expected or unavoidable aspects of the cancer experience, they 
may hesitate to address them with providers and struggle to manage them independently. As AYAs 
consider symptoms within the context of their illness and the medications they are required to take, 
they may decide not to take medications, including oral chemotherapy or other prescribed 
medications, as a means to manage symptoms.33, 34 Viewing nonadherence behaviors in the context of 
symptom self-management rather than regarding them as irrational acts of noncompliance may 
support clinicians in gaining a greater understanding of the AYA's perspective. Exploring with AYAs not 
only the symptoms they are experiencing, but also what they believe is causing them, is an integral 
part of patient-centered symptom assessment and management and supporting patients in symptom 
self-management. 
AYAs' self-management strategies for priority symptoms were also consistent with those reported in 
the initial study using the C-SCAT35 and reflect AYAs' individual preferences and approaches. Although 
medications were frequently reported, particularly for nausea, pain, and difficulty sleeping, most 
strategies were ones that do not require a prescription. Many also align with evidence-based 
guidelines such as balancing activity and rest. Strategies also reflected some AYAs' interest in 
incorporating integrative therapies for symptom self-management. Clinicians need to be aware of the 
range of AYAs' symptom self-management strategies and to ask about perceived efficacy. 
Study results suggest value in clinicians using a structured approach to symptom assessment and 
management and add to the literature addressing the role of electronically administered patient-
reported outcome measures.36, 37 These resources may improve efficiency with regards to collecting 
patient-reported measures to support a more patient-centric approach to care. Adopting a patient-
centered approach that acknowledges the priority symptom/s of the AYA, rather than the clinician, as 
well as the AYA's current self-management strategies and their perceived efficacy supports a more 
personalized approach to symptom assessment and may enhance patient-clinician collaboration in 
symptom management. 
A limitation of this study is the manner in which AYAs designated priority symptoms. The C-SCAT 
allowed users to designate only one priority symptom within each identified cluster. As a consequence, 
priority symptoms may not have been based on rank order. Users who reported more than one 
symptom but did not identify a cluster could designate only one priority symptom. 
Although the C-SCAT has not undergone psychometric evaluation, it includes symptoms and rating 
scales included in the MSAS, a tool with established reliability and validity.20 In addition, the C-SCAT's 
larger focus is not to measure a distinct construct but rather to identify the individual AYA's distinct 
perspective of his/her symptom experience including perceived relationships between symptoms. 
This study demonstrates the C-SCAT's potential to support a personalized approach to symptom 
management through the identification of priority symptoms and the heuristics AYAs use in 
designating priority symptoms. Emphasizing priority symptoms will guide clinicians to a greater 
understanding of the negative impact of symptoms on AYAs' daily lives and foster more meaningful 
personalized interventions to enhance their quality of life. Future studies should evaluate the efficacy 
of the C-SCAT to facilitate improved symptom outcomes. 
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